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In 2018, a cluster of pediatric human parechovirus (HPeV) 
infections in 2 neighboring German hospitals was detected. 
Viral protein 1 sequence analysis demonstrated co-circula-
tion of different HPeV-3 sublineages and of HPeV-1 and -5 
strains, thereby excluding a nosocomial outbreak. Our find-
ings underline the need for HPeV diagnostics and sequence 
analysis for outbreak investigations.
Most human parechovirus (HPeV) infections cause mild upper respiratory tract symptoms or unspecific febrile 
illnesses. Severe clinical manifestations, such as meningitis/
encephalitis, myocarditis, and newborn sepsis, are caused by 
HPeV type 3 (HPeV-3) and have been described in children 
<3 months of age (1). Surveillance data show endemic cir-
culation in several countries, such as the Netherlands (2) and 
the United States (3), but studies have discussed the epidem-
ic potential of HPeV-3 in other countries, including Japan 
(4), Australia (5), and the United Kingdom (6). Nosocomial 
transmission has been documented (7).
However, in most  outbreak investigations, determina-
tion of HPeV types was performed retrospectively (7,8). 
We report on our investigations on a cluster of HPeV infec-
tions in 2 neighboring hospitals in Freiburg, Germany. We 
provide evidence that rapid phylogenetic analysis can assist 
in outbreak investigations.
The Study
During routine diagnostic testing of clinical samples 
from infants and young children in July 2018, we 
detected an increase in HPeV cases (Figure 1). We col-
lected >1 clinical specimens from most patients (Table 
1). During July 9–August 25, 2018, we documented 19 
cases, compared with 4 (2016) and 2 (2017) from this 
same time span, all using the same assays and diagnos-
tic testing algorithm. In September 2018, only 2 patients 
tested HPeV-positive; no additional cases were identi-
fied during October and November 2018. HPeV diagnos-
tic procedures were performed upon the request of the 
treating physician. For the detection of HPeV, we used 
commercial multiplex PCR panels: FTD respiratory 
pathogens 21 (Fast Track Diagnostics [FTD]; Siemens 
Healthineers, https://www.siemens-healthineers.com) 
for respiratory specimens and FTD EPA for cerebrospi-
nal fluid (CSF), plasma, and fecal samples. Patients were 
hospitalized on 1 ward in hospital A and 4 wards in hos-
pital B (Appendix Figure, http://wwwnc.cdc.gov/EID/
article/25/7/19-0257-App1.pdf). We retrieved medical 
data on HPeV-positive patients from the hospital-based 
information system. We obtained written informed con-
sent from parents or guardians. 
The age of the 2018 HPeV-positive patients ranged 
from 10 days to 19 months (median 1 month), with 88% of 
patients being <4 months of age (Table 1). Plasma samples 
(n = 14) had a diagnostic yield of 100%. The median dura-
tion of hospitalization was 4 days (range 3–23 days). The 
main clinical symptoms of HPeV-3 cases were fever (n = 
21; 100%) and poor feeding (n = 16; 76%) (Table 2). None 
of our patients required admission to a pediatric intensive 
care unit. All of our patients were discharged from the hos-
pital without complications.
After we detected the first cases in July 2018, we 
performed molecular typing of HPeV by amplifying and 
sequencing the complete viral protein 1 (VP1) genomic 
region (9). Of the 25 HPeV strains detected in Freiburg 
in 2018, 21 were typed as HPeV-3, 2 were assigned to 
HPeV-1, and 2 to HPeV-5 (Table 1). This compares with 
7 HPeV-1 and 6 HPeV-3 types in Freiburg in 2016, and 
3 HPeV-1, 3 HPeV-3, and 5 strains not typed in 2017 
(Figure 1).
For phylogenetic analyses, we included HPeV 
strains detected during January 2016–September 2018 
at another 4 university hospitals: Würzburg (n = 56) 
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and Erlangen (n = 10) in southern Germany, Bonn 
(n = 10) in western Germany, and Charité Berlin (n = 
14) in northeastern Germany. We detected 134 HPeV 
strains in respiratory, fecal, CSF, and serum samples. 
These were typed based on the VP1 genomic region (9). 
We detected HPeV types 1, 3, 4, 5, and 6. We depos-
ited all sequences in GenBank under accession numbers 
MK204942–MK204985 and MK291273–MK291362 
(Appendix Tables 1, 2). For HPeV-3 phylogenetic 
analysis, we included 74 strains identified during 2016–
2018 and compared them with representative reference 
strains available from GenBank (Figure 2). Because of 
high nucleotide variability in the 3′ end of the VP1 cod-
ing region, we included only complete VP1 sequences.
As recently described, 2 HPeV-3 lineages have been 
identified (10). Widespread clustering proved co-circula-
tion of the 2016–2018 HPeV strains from Germany (Fig-
ure 2). One cluster comprising German strains was most 
closely related to HPeV-3 identified in Japan (98.82% nt 
identity), Australia (98.82%), and the United Kingdom 
(99.12%).
Among the 21 Freiburg 2018 HPeV-3 strains, 3 groups 
of completely identical VP1 sequences (10, 3, and 2 se-
quences) were observed. However, no separate clustering 
could be detected among these strains because HPeV se-
quences from other regions in Germany also were assigned 
to these groups. A direct epidemiologic link could be 
drawn between 2 cases (cases 12 and 14, with completely 
identical VP1 sequences, were in twins;  Figure 2). Another 
2 cases (cases 15 and 18) shared time on the same ward 
and also displayed 100% identical sequences. However, no 
hospital ward–specific clustering was observed, suggesting 
community-acquired transmission.
Conclusions
Routine diagnostics showed an unexpectedly high num-
ber of HPeV cases during a 6-week period in 2 neighbor-
ing hospitals in Freiburg, Germany. This raised concern 
about the possibility of a nosocomial outbreak. Recently, 
healthcare-associated transmission of HPeV-3 has been 
described. This makes timely identification of outbreaks 
essential from a hospital hygiene, as well as a public 
health, perspective (7).
Several patients showed signs of sepsis-like illness, 
including the clinical triad of fever, poor feeding, and 
irritability. This is similar to a UK case series reporting 
a cluster of HPeV infections among infants in 2016 (6). 
In our study, HPeV-3 was detected exclusively in CSF 
samples, indicating a more severe clinical phenotype 
compared with HPeV-1 and -5 infections, supporting pre-
vious data (11). Studies have shown that rapid detection 
of HPeV reduced length of hospital stay and antimicrobial 
drug use. This emphasizes the usefulness of HPeV diag-
nostics (1). We showed that HPeV diagnostics, including 
molecular typing, helped to exclude a nosocomial out-
break. Diagnostically, plasma, respiratory swab, and fecal 
samples all showed high detection rates, and most patients 
were positive in >1 area. Testing of blood samples for en-
terovirus detection was recently proposed for infants and 
should be considered for HPeV accordingly (12).
We demonstrated different HPeV types and sublin-
eages, including 2 rare HPeV-5 infections. By conduct-
ing phylogenetic analysis in combination with review-
ing epidemiologic data, we could exclude a nosocomial 
outbreak. However, based on this information, transmis-
sions could not be ruled out in 2 independent events with 
2 cases each. Although a cluster of HPeV-3 infections 
has been described (6), retrospective sequence analy-
sis showed different clustering of the identified strains 
(13). Because of low nucleotide variability, sequence-
based differentiation between HPeV-3 strains remains 
Figure 1. Number of human parechovirus (HPeV) cases in infants 
and young children by month, Freiburg, Germany, 2016–2018.
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ambiguous, a circumstance that impedes molecular out-
break investigation (14).
Our study has limitations. There is a lack of available 
sequence data from pediatric patients in Germany. In con-
trast to reports from the Netherlands and the UK, a bian-
nual cycle of HPeV infections has not been demonstrated 
in Germany; however, our data suggest a biannual cycle. 
From a public health perspective, a central repository for 
HPeV sequences, together with key anonymized clinical 
data from human cases, would improve our understanding 
of HPeV epidemiology and virus evolution. Institutional-
ized surveillance similar to the enterovirus surveillance 
and typing systems already in place across Europe could 
serve as a blueprint (8,15).
Our report underscores the usefulness of HPeV diag-
nostics in infants. It illustrates the power of VP1 sequence– 
guided phylogenetic HPeV analysis, which helped, in com-
bination with epidemiologic data, to rapidly investigate an 
HPeV outbreak.
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Figure 2. A) Phylogenetic analysis of human parechovirus type 3 strains 
collected during 2016–2018 from patients hospitalized in Freiburg, 
Germany, along with strains from 4 geographic regions in Germany 
based on the viral protein 1 region (678 nt) of the polyprotein gene  
(n = 74). B) Phylogenetic analysis of Yamagata/2011 parechovirus 
lineage. Color code depicts wards in the 2 Freiburg hospitals: green,  
A3; red, B1; pink, B3; purple, B4. Cases in twins are marked with open 
circles. Scale bars indicate nucleotide substitutions per site.
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Antibiotics and similar drugs, together called 
antimicrobial agents, have been used for the 
past 70 years to treat patients who have infec-
tious diseases. Since the 1940s, these drugs 
have greatly reduced illness and death from 
infectious diseases. However, these drugs 
have been used so widely and for so long that 
the infectious organisms the antibiotics are 
designed to kill have adapted to them, mak-
ing the drugs less effective.
Each year in the United States, at least 2 mil-
lion people become infected with bacteria 
that are resistant to antibiotics and at least 
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Appendix Table 1. Sample type, GenBank accession number, and strain ID of human parechovirus cases, Freiburg, Germany, January–
September 2018* 
Case 










4 Fecal MK204944 FR.2423/BW/DE/2018 
5 Fecal MK204971 FR.2429/BW/DE/2018 
6 Fecal MK204980 FR.2430/BW/DE/2018 
7 Fecal MK204976 FR.2431/BW/DE/2018 
8 Fecal MK204970 FR.2432/BW/DE/2018 
9 Fecal MK204956 FR.2433/BW/DE/2018 
10 Plasma MK204954 FR.4424/BW/DE/2018 
11 Fecal MK204958 FR.2425/BW/DE/2018 
12 Fecal MK204962 FR.2427/BW/DE/2018 
13 CSF MK204963 FR.3428/BW/DE/2018 
14 Fecal MK204957 FR.2426/BW/DE/2018 
15 Fecal MK204966 FR.2434/BW/DE/2018 
16 Fecal MK204955 FR.2435/BW/DE/2018 
17 Fecal MK204972 FR.2436/BW/DE/2018 





20 Fecal MK204967 FR.2440/BW/DE/2018 
21 Fecal MK204977 FR.2439/BW/DE/2018 
22 Fecal MK204965 FR.2441/BW/DE/2018 
23 Fecal MK204943 FR.2442/BW/DE/2018 
24 Fecal MK204979 FR.2443/BW/DE/2018 
25 Plasma MK204942 FR.4444/BW/DE/2018 
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Appendix Table 2. GenBank accession number, strain ID, specimen type, year of sampling and human parechovirus (HPeV) type of cases in 
Bonn (BN), Charité Berlin (BE), Erlangen (ER), Freiburg (FR; 2016–2017 only), and Würzburg (WB), Germany, January 2016–September 
2018 
Accession no. Strain ID Specimen type Year HPeV type 
MK291287 BN.3101/NW/DE/2018 Cerebrospinal fluid 2018 3 
MK291288 BN.1102/NW/DE/2016 Respiratory 2016 1 
MK291291 BN.2103/NW/DE/2016 Fecal 2016 3 
MK291289 BN.1104/NW/DE/2017 Respiratory 2017 3 
MK291292 BN.2105/NW/DE/2017 Fecal 2017 3 
MK291295 BN.3106/NW/DE/2017 Cerebrospinal fluid 2017 3 
MK291293 BN.2107/NW/DE/2017 Fecal 2017 3 
MK291290 BN.1108/NW/DE/2018 Respiratory 2018 3 
MK291294 BN.2109/NW/DE/2018 Fecal 2018 1 
MK291296 BN.3110/NW/DE/2018 Cerebrospinal fluid 2018 3 
MK291275 BE.2201/HE/DE/2016 Fecal 2016 3 
MK291273 BE.1202/BE/DE/2016 Respiratory 2016 1 
MK291276 BE.2203/BE/DE/2017 Fecal 2017 3 
MK291286 BE.4204/BE/DE/2018 Serum 2018 6 
MK291274 BE.1205/BE/DE/2018 Respiratory 2018 4 
MK291284 BE.3206/BE/DE/2018 Cerebrospinal fluid 2018 3 
MK291285 BE.3207/BE/DE/2018 Cerebrospinal fluid 2018 3 
MK291277 BE.2208/BE/DE/2018 Fecal 2018 3 
MK291278 BE.2209/HE/DE/2018 Fecal 2018 3 
MK291279 BE.2210/BB/DE/2018 Fecal 2018 3 
MK291280 BE.2211/HE/DE/2018 Fecal 2018 5 
MK291281 BE.2212/HE/DE/2018 Fecal 2018 3 
MK291282 BE.2213/BE/DE/2018 Fecal 2018 3 
MK291283 BE.2214/HE/DE/2018 Fecal 2018 4 
MK291297 ER.1301/BY/DE/2018 Respiratory 2018 5 
MK291303 ER.2302/BY/DE/2018 Fecal 2018 3 
MK291298 ER.1303/BY/DE/2018 Respiratory 2018 3 
MK291304 ER.2304/BY/DE/2018 Fecal 2018 3 
MK291305 ER.2305/BY/DE/2018 Fecal 2018 5 
MK291299 ER.1306/BY/DE/2018 Respiratory 2018 3 
MK291300 ER.1307/BY/DE/2018 Respiratory 2018 1 
MK291301 ER.1308/BY/DE/2018 Respiratory 2018 1 
MK291306 ER.2309/BY/DE/2018 Fecal 2018 5 
MK291302 ER.1310/BY/DE/2018 Respiratory 2018 3 
MK204981 FR.4401/BW/DE/2016 Plasma 2016 3 
MK204985 FR.1402/BW/DE/2016 Respiratory 2016 3 
MK204983 FR.4403/BW/DE/2016 Plasma 2016 3 
MK204984 FR.2404/BW/DE/2016 Fecal 2016 1 
MK204950 FR.1405/BW/DE/2016 Respiratory 2016 1 
MK204982 FR.1406/BW/DE/2016 Respiratory 2016 1 
MK204949 FR.1407/BW/DE/2016 Respiratory sample 2016 1 
MK204948 FR.2408/BW/DE/2016 Fecal 2016 1 
MK204953 FR.1409/BW/DE/2016 Respiratory 2016 1 
MK204947 FR.2410/BW/DE/2016 Fecal 2016 1 
MK204960 FR.4411/BW/DE/2016 Plasma 2016 3 
MK204959 FR.4412/BW/DE/2016 Plasma 2016 3 
MK204961 FR.2413/BW/DE/2016 Fecal 2016 3 
MK204946 FR.1414/BW/DE/2017 Respiratory 2017 1 
MK204973 FR.3415/BW/DE/2017 Cerebrospinal fluid 2017 3 
MK204952 FR.1416/BW/DE/2017 Respiratory 2017 1 
MK204974 FR.4417/BW/DE/2017 Plasma 2017 3 
MK204978 FR.3418/BW/DE/2017 Cerebrospinal fluid 2017 3 
MK204945 FR.1419/BW/DE/2017 Respiratory 2017 1 
MK291307 WB.1501.BY/2016/DEU Respiratory 2016 1 
MK291308 WB.1502.BY/2016/DEU Respiratory 2016 1 
MK291309 WB.1503.BY/2016/DEU Respiratory 2016 1 
MK291310 WB.1504.BY/2016/DEU Respiratory 2016 1 
MK291311 WB.1505.BY/2016/DEU Respiratory 2016 1 
MK291312 WB.1506.BY/2016/DEU Respiratory 2016 3 
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Accession no. Strain ID Specimen type Year HPeV type 
MK291313 WB.1507.BY/2016/DEU Respiratory 2016 3 
MK291314 WB.1508.BY/2016/DEU Respiratory 2016 1 
MK291315 WB.1509.BY/2016/DEU Respiratory 2016 4 
MK291316 WB.1510.BY/2016/DEU Respiratory 2016 1 
MK291317 WB.1511.BY/2016/DEU Respiratory 2016 1 
MK291318 WB.1512.BY/2016/DEU Respiratory 2016 3 
MK291319 WB.1513.BY/2016/DEU Respiratory  2016 1 
MK291320 WB.1514.BY/2016/DEU Respiratory  2016 1 
MK291321 WB.1515.BY/2016/DEU Respiratory  2016 1 
MK291322 WB.1516.BY/2017/DEU Respiratory  2017 1 
MK291323 WB.1517.BY/2017/DEU Respiratory  2017 4 
MK291324 WB.1518.BY/2017/DEU Respiratory  2017 3 
MK291325 WB.1519.BY/2017/DEU Respiratory  2017 1 
MK291326 WB.1520.BY/2017/DEU Respiratory  2017 1 
MK291354 WB.2521.BY/2017/DEU Fecal 2017 3 
MK291327 WB.1522.BY/2017/DEU Respiratory  2017 1 
MK291328 WB.1523.BY/2017/DEU Respiratory  2017 3 
MK291329 WB.1524.BY/2017/DEU Respiratory  2017 1 
MK291362 WB.3525.BY/2017/DEU Cerebrospinal fluid 2017 3 
MK291355 WB.2526.BY/2017/DEU Fecal 2017 3 
MK291330 WB.1527.BY/2017/DEU Respiratory  2017 1 
MK291356 WB.2528.BY/2017/DEU Fecal 2017 3 
MK291357 WB.2529.BY/2017/DEU Fecal 2017 3 
MK291331 WB.1530.BY/2017/DEU Respiratory  2017 1 
MK291332 WB.1531.BY/2017/DEU Respiratory  2017 3 
MK291333 WB.1532.BY/2017/DEU Respiratory  2017 3 
MK291334 WB.1533.BY/2017/DEU Respiratory  2017 1 
MK291335 WB.1534.BY/2017/DEU Respiratory  2017 3 
MK291336 WB.1535.BY/2017/DEU Respiratory  2017 1 
MK291337 WB.1536.BY/2017/DEU Respiratory  2017 6 
MK291338 WB.1537.BY/2017/DEU Respiratory  2017 1 
MK291339 WB.1538.BY/2017/DEU Respiratory  2017 6 
MK291358 WB.2539.BY/2017/DEU Fecal 2017 3 
MK291340 WB.1540.BY/2017/DEU Respiratory  2017 1 
MK291341 WB.1541.BY/2017/DEU Respiratory  2017 6 
MK291342 WB.1542.BY/2017/DEU Respiratory  2017 4 
MK291343 WB.1543.BY/2017/DEU Respiratory  2017 6 
MK291344 WB.1544.BY/2017/DEU Respiratory  2017 6 
MK291345 WB.1545.BY/2017/DEU Respiratory  2017 3 
MK291346 WB.1547.BY/2017/DEU Respiratory  2017 3 
MK291347 WB.1548.BY/2018/DEU Respiratory  2018 1 
MK291348 WB.1549.BY/2018/DEU Respiratory  2018 3 
MK291349 WB.1550.BY/2018/DEU Respiratory  2018 6 
MK291350 WB.1551.BY/2018/DEU Respiratory  2018 6 
MK291351 WB.1552.BY/2018/DEU Respiratory  2018 1 
MK291352 WB.1553.BY/2018/DEU Respiratory  2018 3 
MK291353 WB.1554.BY/2018/DEU Respiratory  2018 3 
MK291359 WB.2555.BY/2018/DEU Fecal 2018 3 
MK291360 WB.2556.BY/2018/DEU Fecal 2018 3 









Appendix Figure. Length of stay on assigned wards of 19 patients with human parechovirus, Freiburg, Germany, July 9–August 25, 2018. 
 
 
 
